Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the development and commercialization of therapies. The company is engaged in complement inhibition and has developed and commercialized two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria, as well as the complement inhibitor to treat atypical hemolytic uremic syndrome and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. In addition, the company has two enzyme replacement therapies for patients with metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency.
  • TickerALXN
  • ISINUS0153511094
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Laura Chico

Passing the Baton - CFO Clancy to Step Down, Sarin Appointed

Laura Chico

Drilling Into the ALXN/AMGN IPR Challenge - KOL Call Takeaways

Laura Chico

Wedbush Advisor Call -- TODAY 9/17/19 @ 10:30AM ET

Laura Chico

Passing the Baton - CFO Clancy to Step Down, Sarin Appointed

Laura Chico

Drilling Into the ALXN/AMGN IPR Challenge - KOL Call Takeaways

Laura Chico

Wedbush Advisor Call -- TODAY 9/17/19 @ 10:30AM ET

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

MarketLine Department

MorphoSys AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's MorphoSys AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by MorphoSys AG since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlight...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • We are upgrading Health Care to an overweight. XLV is breaking topside a bullish base and reversing a 9-month RS downtrend. • Biotechs are leadership and are breaking out of bullish consolidation. XBI and IBB are constructive and making positive inflections. • Energy remains a leadership Sector with many bullish bases that are still unexploited. We have highlighted a number of them in today's Vital Signs.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch